Peroxisome proliferator‐activated receptor gamma in human prostate carcinoma

Peroxisome proliferator‐activated receptor (PPAR) is a member of the nuclear hormone receptor superfamily of transcription factors. Peroxisome proliferator‐activated receptor gamma (PPARγ) plays an important role in the regulation of lipid homeostasis, adipogenesis, insulin resistance, and development of various organs. Agonists of PPARγ have been also reported to inhibit proliferation of prostate carcinoma cells as in other human malignancies, and these synthetic ligands have been used in differentiation‐mediated therapy of various human carcinomas associated with high levels of PPARγ. The significance of PPARγ expression, however, was unknown in human prostate carcinoma tissues. The purpose of the present study was therefore to examine the immunolocalization of PPARγ in human prostate cancer tissues (40 cases) and correlate the findings with clinicopathological features of the patients in order to evaluate its possible biological significance. Twenty‐nine patients were positive for PPARγ immunoreactivity (73%) and a significant inverse correlation was detected between PPARγ immunoreactivity, pT stage (P = 0.036), and serum concentration of prostate‐specific antigen (P = 0.0004). In conclusion, PPARγ immunoreactivity is considered to be a new clinicopathological parameter of human prostate cancer.

[1]  I. Giannopoulou,et al.  Peroxisome proliferator-activated receptor gamma expression in urothelial carcinomas of the bladder: association with differentiation, proliferation and clinical outcome. , 2009, European Journal of Surgical Oncology.

[2]  M. Terris,et al.  PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database. , 2008, European urology.

[3]  R. Yoshimura,et al.  Peroxisome Proliferator-Activated Receptor-γ Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer , 2008, PPAR research.

[4]  F. DeMayo,et al.  Peroxisome Proliferator-Activated Receptor γ Is a Target of Progesterone Regulation in the Preovulatory Follicles and Controls Ovulation in Mice , 2008, Molecular and Cellular Biology.

[5]  A. Krishnan,et al.  Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae , 2007 .

[6]  I. Voutsadakis.  Peroxisome proliferator-activated receptor γ (PPARγ) and colorectal carcinogenesis , 2007, Journal of Cancer Research and Clinical Oncology.

[7]  R. Seger,et al.  MAPK- Kinases as Nucleo-Cytoplasmic Shuttles for PPARγ , 2007, Cell cycle.

[8]  S. Culine,et al.  Peroxisome Proliferator-Activated Receptor γ Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer , 2006, Molecular and Cellular Biology.

[9]  Takashi Suzuki,et al.  Peroxisome Proliferator-Activated Receptor γ and Growth Inhibition by Its Ligands in Uterine Endometrial Carcinoma , 2006, Clinical Cancer Research.

[10]  Takashi Suzuki,et al.  Steroid sulfatase and estrogen sulfotransferase in human prostate cancer , 2006, The Prostate.

[11]  Takashi Suzuki,et al.  In situ androgen production in human gastric carcinoma--androgen synthesizing and metabolizing enzymes. , 2006, Anticancer research.

[12]  T Suzuki,et al.  Peroxisome proliferator-activated receptor gamma in human breast carcinoma: a modulator of estrogenic actions. , 2006, Endocrine-related cancer.

[13]  Takashi Suzuki,et al.  In situ androgen producing enzymes in human prostate cancer. , 2005, Endocrine-related cancer.

[14]  G. Rice,et al.  Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma , 2004, British Journal of Cancer.

[15]  P. Härkönen,et al.  Role of estrogens in development of prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  Takashi Suzuki,et al.  Steroid Sulfatase and Estrogen Sulfotransferase in Human Endometrial Carcinoma , 2004, Clinical Cancer Research.

[17]  D. Albanes,et al.  Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study. , 2003, Cancer letters.

[18]  Xin Wang,et al.  Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells , 2002, Molecular and Cellular Endocrinology.

[19]  Biaoyang Lin,et al.  The program of androgen-responsive genes in neoplastic prostate epithelium , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  H. Sasaki,et al.  Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. , 2002, Japanese journal of clinical oncology.

[21]  A. Shuldiner,et al.  The role of peroxisome proliferator-activated receptor gamma in diabetes and obesity , 2002, Current diabetes reports.

[22]  H. Sasaki,et al.  Decreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancer. , 2002, Lung cancer.

[23]  K. Hattori,et al.  Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. , 2001, The American journal of pathology.

[24]  E. Williamson,et al.  Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. , 2001, Cancer Research.

[25]  M. Carey,et al.  Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Cancer research.

[26]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[28]  B. Spiegelman,et al.  Loss-of-Function Mutations in PPARγ Associated with Human Colon Cancer , 1999 .

[29]  J. Auwerx,et al.  An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer , 1999, Cellular and Molecular Life Sciences CMLS.

[30]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[31]  C. López-Otín,et al.  Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. , 1998, Endocrine reviews.

[32]  J Auwerx,et al.  Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. , 1996, Journal of lipid research.

[33]  H. Sasano,et al.  Immunolocalization of oestrogen and progesterone receptors in prostatic hyperplasia and carcinoma , 1996, Histopathology.

[34]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[35]  B. Spiegelman,et al.  mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. , 1994, Genes & development.

[36]  A. Krishnan,et al.  Biology of PPAR gamma in cancer: a critical review on existing lacunae. , 2007, Current molecular medicine.

[37]  I. Voutsadakis.  Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. , 2007, Journal of cancer research and clinical oncology.

[38]  H. Koeffler.  Peroxisome proliferator-activated receptor γ and cancers , 2003 .

[39]  H. Koeffler.  Peroxisome proliferator-activated receptor gamma and cancers. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Auwerx,et al.  The pleiotropic functions of peroxisome proliferator-activated receptor γ , 2001, Journal of Molecular Medicine.

[41]  Rajnish A. Gupta,et al.  15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.

[42]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor γ ligand, 15-deoxy-Δ12,14-prostaglandin J2 , 2000 .

[43]  D. Tindall,et al.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[44]  B. Spiegelman,et al.  Loss-of-function mutations in PPAR gamma associated with human colon cancer. , 1999, Molecular cell.

[45]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[46]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. , 1996, Annual review of cell and developmental biology.